Denovo Biopharma
Dr. Alphs has a MD and PhD from the University of Chicago. He has had 10 years of experience in academia including psychiatric practice, and over 20 years of experience in industry. He has led work in all phases of clinical development from Phase I to IV with positions at Novartis, Knoll Pharmaceuticals, Pfizer, Janssen, Newron, and currently at Denovo Biopharma. He has led programs in numerous CNS disorders, including schizophrenia, bipolar disorder, suicidality, anxiety, depression, epilepsy, neuropathic pain, traumatic brain injury, and Rett Syndrome. He has authored over 200 publications, and developed several scales used in clinical trials, including for negative symptoms of schizophrenia, extrapyramidal symptoms, and suicide assessment.
This person is not in any offices
Denovo Biopharma
Denovo Biopharma is a private San Diego-based biotech company, also operating in China, providing a novel biomarker solution to personalize drug development. The core technology of the company is its industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples.